INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Scotiabank

Scotiabank began coverage on shares of INmune Bio (NASDAQ:INMB) in a research report issued on Thursday, Briefing.com reports. The firm set a “sector outperform” rating and a $22.00 price target on the stock. Scotiabank’s target price would indicate a potential upside of 221.17% from the stock’s previous close.

INmune Bio Trading Up 2.4 %

NASDAQ:INMB opened at $6.85 on Thursday. The company has a 50-day moving average of $7.98 and a 200-day moving average of $10.02. INmune Bio has a twelve month low of $6.41 and a twelve month high of $14.74. The firm has a market cap of $135.51 million, a price-to-earnings ratio of -3.57 and a beta of 1.93.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.41% and a negative net margin of 26,333.59%.

Insider Transactions at INmune Bio

In other INmune Bio news, Director Scott Juda purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were purchased at an average cost of $7.27 per share, with a total value of $36,350.00. Following the completion of the transaction, the director now owns 71,603 shares of the company’s stock, valued at $520,553.81. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 35.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On INmune Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Advocates Investment Management raised its holdings in shares of INmune Bio by 8.6% during the fourth quarter. Financial Advocates Investment Management now owns 12,500 shares of the company’s stock worth $141,000 after acquiring an additional 990 shares in the last quarter. Fermata Advisors LLC grew its stake in shares of INmune Bio by 6.9% in the 1st quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock valued at $370,000 after buying an additional 2,025 shares in the last quarter. Westside Investment Management Inc. increased its holdings in INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after buying an additional 10,950 shares during the last quarter. Rhumbline Advisers bought a new position in INmune Bio during the second quarter valued at approximately $121,000. Finally, Bank of New York Mellon Corp raised its position in INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.